Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Gojo

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Blood Advances|March 27, 2020
The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicingW Brian Dalton, Eric Helmenstine, Lisa Pieterse, et al.
Leukemia Research|August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.
Cancer Chemotherapy and Pharmacology|August 17, 2013
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemiasIvana Gojo, Mariola Sadowska, Alison Walker, et al.
Blood|May 22, 2024
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemiaFrancesco Mazziotta, Luca Biavati, Joseph Rimando, et al.
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Blood|December 21, 2006
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasIvana Gojo, Anchalee Jiemjit, Jane B Trepel, et al.
Transplantation and Cellular Therapy|September 2, 2021
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous LeukemiaNicholas P Tschernia, Vaibhav Kumar, Dominic T Moore, et al.
American Journal of Hematology|June 2, 2005
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemiaSteven D Gore, B Douglas Smith, Ivana Gojo, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 17, 2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemiaKyle Zacholski, Bryan Hambley, Erin Hickey, et al.
Haematologica|November 2, 2013
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivoLeena Chaudhuri, Nicole D Vincelette, Brian D Koh, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Blood Advances|March 27, 2020
The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicingW Brian Dalton, Eric Helmenstine, Lisa Pieterse, et al.
Leukemia Research|August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.
Cancer Chemotherapy and Pharmacology|August 17, 2013
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemiasIvana Gojo, Mariola Sadowska, Alison Walker, et al.
Blood|May 22, 2024
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemiaFrancesco Mazziotta, Luca Biavati, Joseph Rimando, et al.
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Blood|December 21, 2006
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasIvana Gojo, Anchalee Jiemjit, Jane B Trepel, et al.
Transplantation and Cellular Therapy|September 2, 2021
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous LeukemiaNicholas P Tschernia, Vaibhav Kumar, Dominic T Moore, et al.
American Journal of Hematology|June 2, 2005
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemiaSteven D Gore, B Douglas Smith, Ivana Gojo, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 17, 2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemiaKyle Zacholski, Bryan Hambley, Erin Hickey, et al.
Haematologica|November 2, 2013
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivoLeena Chaudhuri, Nicole D Vincelette, Brian D Koh, et al.
Pageof 13